Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in melanoma
- New trial
Melanoma
Randomized trial compares comprehensive margin assessment with standard pathology after melanoma surgery
The University of Nebraska is conducting a randomized study comparing two methods of examining tissue removed during wide local excision (WLE) for Stage I–II cutaneous melanoma, including acral melanoma. All…
NCT07869381 Exploratory - New trial
Melanoma
Phase 2 pilot uses ctDNA to guide checkpoint-inhibitor discontinuation in advanced melanoma with disease control
Rutgers Cancer Institute of New Jersey is conducting a pilot study of serial circulating tumor DNA (ctDNA) measurements to help guide discontinuation of immune checkpoint treatment in unresectable stage III or…
NCT07830225 Exploratory - Trial result Spotlight
Melanoma
Lifileucel produces confirmed responses in 2 of 3 treated adolescents with ICI-refractory metastatic melanoma
Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy (adult US accelerated approval) given after cyclophosphamide/fludarabine lymphodepletion and followed by up to six doses of high-dose IL-2; here…
NCT06566092 - New trial Spotlight
Melanoma
Phase 3 darovasertib PKC inhibitor plus crizotinib c-MET/ALK inhibitor in adjuvant uveal melanoma
IDEAYA Biosciences’ OptimUM-11 is a randomized, multi-center, open-label Phase 3 study testing whether adjuvant darovasertib (IDE196; a small-molecule protein kinase C inhibitor) combined with crizotinib (a…
NCT07804186 Registrational - New trial Spotlight
Melanoma
Phase 3 iSCIB1+ gp100/TRP-2 DNA vaccine adds melanoma antigen targeting to PD-1/CTLA-4 blockade.
Scancell Ltd’s adaptive, multicenter Phase 3 trial randomizes adults with unresectable Stage III/IV melanoma to iSCIB1+ (a DNA “Immunobody” vaccine encoding melanoma antigens gp100 and TRP-2 to drive antigen-specific…
NCT07815574 Registrational - New trial
Melanoma
Phase 2 NASA tests pembrolizumab PD‑1 blockade vs ipilimumab CTLA‑4 + nivolumab PD‑1 in resectable melanoma.
This randomized Phase 2 study at UNC Lineberger Comprehensive Cancer Center asks whether a short neoadjuvant checkpoint regimen can safely replace the usual months-long postoperative (adjuvant) systemic therapy in…
NCT07740941 Exploratory - Trial result Spotlight
Melanoma
Spartalizumab (PD-1) + Dabrafenib/Trametinib Extends OS vs BRAF/MEK Alone in BRAF V600 Melanoma
Spartalizumab is an anti–PD-1 monoclonal antibody combined here with dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) as first-line targeted therapy intensification for BRAF V600-mutant…
NCT02967692 - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result Spotlight
Melanoma
Ipilimumab (CTLA-4) + nivolumab–relatlimab (PD-1/LAG-3) drives 69% MPR (63% pCR) in resectable stage III melanoma—at the cost of 26% G3 and 1 G5 myocarditis
Neoadjuvant INR combines low-dose ipilimumab (CTLA-4 blockade) with fixed-dose nivolumab–relatlimab (PD-1/LAG-3 blockade) to deepen pathologic responses while keeping treatment short. In this Phase II trial in…
NCT06295159 - Trial result Spotlight
Melanoma
Nivolumab + Relatlimab (PD-1/LAG-3) Adds 10% Absolute 5-Year OS in 1L Melanoma
Nivolumab is a PD-1 inhibitor and relatlimab is a LAG-3 inhibitor evaluated as a fixed-dose combination versus nivolumab alone in the randomized, double-blind Phase 3 RELATIVITY-047 first-line trial in…
NCT03470922 - Trial result
Melanoma
TIL adoptive cell therapy (autologous) delivers 22% ORR in metastatic uveal melanoma—responses track with UMIS-selected, tumor-reactive products
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy—generated from resected metastases, expanded ex vivo, then given after cyclophosphamide/fludarabine lymphodepletion with high-dose IL-2—was tested…
NCT03467516 - Trial result
Melanoma
Adaptive encorafenib/binimetinib (BRAF/MEK) + nivolumab cuts Grade 3+ AEs while preserving long-run disease control in BRAF V600E melanoma
Encorafenib (BRAF inhibitor) + binimetinib (MEK inhibitor) were given either continuously or via patient-specific adaptive scheduling (ctDNA- and imaging-calibrated mathematical model), with nivolumab (anti–PD-1)…
NCT03543969 - Trial result
Melanoma
Recent anti-CTLA-4 (ipilimumab) linked to IL-6–high immunosuppressive profile and ~6× shorter OS on PD-L1 + CD40/4-1BB adenoviral gene therapy in PD-1–refractory melanoma
LOKON003 combines an anti–PD-L1 antibody with a replication-competent adenoviral immunogene therapy designed to stimulate CD40 and 4-1BB signaling (NCT04123470) in anti–PD-1–refractory metastatic melanoma (Phase…
NCT04123470 - Trial result
Melanoma
Brenetafusp (PRAME×CD3 ImmTAC) shows 17% ORR at 160µg in late-line melanoma, with mostly low-grade CRS and no irAE recurrence
Brenetafusp (IMC-F106C) is a PRAME-targeted ImmTAC bispecific (PRAME×CD3) designed to redirect polyclonal T cells into PRAME-expressing tumors; in this Phase 1 study (NCT04262466), HLA-A*02:01+ advanced melanoma…
NCT04262466 - Trial result
Melanoma
Botensilimab (Fc‑enhanced anti‑CTLA‑4) + balstilimab (anti‑PD‑1) delivers 22% ORR in dual ICI‑refractory cutaneous melanoma
Botensilimab (BOT) is an Fc‑engineered anti‑CTLA‑4 antibody designed to enhance T‑cell priming and Treg depletion, and balstilimab (BAL) is an anti‑PD‑1; both were evaluated in the open-label global Phase 2 C‑800‑23…
NCT05529316 - Trial result
Melanoma
Imneskibart (AU-007) IL-2–CD25 “decoy” antibody + low-dose aldesleukin drives tumor shrinkage in CPI-refractory melanoma (early PFS signal)
Imneskibart (AU-007) is an AI-designed anti–IL-2 monoclonal antibody that blocks IL-2 binding to CD25 (trimeric IL-2R) while preserving signaling through CD122/CD132 (dimeric IL-2R), aiming to expand Teff/NK without…
NCT05267626 - Trial result
Melanoma
IO102-IO103 (PD-L1/IDO peptide vaccine) + nivolumab–relatlimab (PD-1/LAG-3) posts 60% ORR in 1L unresectable melanoma
IO102-IO103 is a subcutaneous peptide vaccine targeting PD-L1 and IDO-expressing tumor and immunosuppressive cells, combined here with nivolumab–relatlimab (dual PD-1/LAG-3 checkpoint blockade) in a multicenter Phase…
NCT05912244 - Trial result
Melanoma
OBX-115 (ACZ-inducible mbIL15–armored TIL) drives 67% ORR in post-ICI advanced melanoma without high-dose IL2
OBX-115 is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express membrane-bound IL15 (mbIL15) under small-molecule control with acetazolamide (ACZ), designed to avoid the traditional…
NCT06060613 - Trial result
Melanoma
Atezolizumab + Tiragolumab (PD-L1/TIGIT) Shows Index Node pCR Can Miss Melanoma
Atezolizumab is an anti–PD-L1 antibody and tiragolumab is an anti-TIGIT antibody evaluated in a preplanned NeoACTIVATE Arm C substudy (NCT03554083) asking whether clipped index lymph node (ILN) pathology can…
NCT03554083 - New trial
Melanoma
Phase 1 Circadian-Optimized Light Therapy (COLT) supports TIL cell therapy via circadian entrainment.
This single-center, prospective Phase 1 pilot from City of Hope tests whether Circadian-Optimized Light Therapy (COLT)—a timed morning light-exposure program delivered through the Circadian OS iPad app—can be safely…
NCT07628894 Exploratory - Trial result
Melanoma
Tebentafusp (gp100×CD3 ImmTAC) Doubles 5-Year OS to 16% in HLA-A*02:01+ Metastatic Uveal Melanoma
Tebentafusp is a first-in-class TCR–anti-CD3 bispecific fusion protein (ImmTAC) that redirects T cells to gp100 peptide presented by HLA-A*02:01 on uveal melanoma cells. In the international, open-label Phase 3…
NCT03070392 - Trial result
Melanoma
Pegenzileukin (SAR444245) non‑α IL‑2 (IL‑2Rβγ agonist) + PD‑1 cemiplimab hits 40% ORR in metastatic melanoma; 56% ORR in advanced cSCC
Pegenzileukin is a pegylated recombinant IL‑2 variant engineered to avoid IL‑2Rα binding (aiming to reduce classic IL‑2 toxicities/Treg expansion) while engaging IL‑2Rβγ to expand NK and CD8 T cells; here it was…
NCT04913220 - Trial result
Melanoma
Sotigalimab (intratumoral CD40 agonist) + pembrolizumab delivers 50% ORR and abscopal activity in metastatic melanoma
Sotigalimab (APX005M) is an intratumoral CD40 agonistic antibody designed to activate antigen-presenting cells (APCs); here it was combined with systemic pembrolizumab (anti–PD-1) in an ICB-naïve metastatic melanoma…
NCT02706353 - Trial result Spotlight
Melanoma
DC-ATA personal dendritic cell vaccine + PD-1/LAG-3 blockade produced responses in all 6 response-evaluable patients with metastatic melanoma.
Personal DC-ATA is an autologous dendritic-cell vaccine loaded ex vivo with lysate from a short-term autologous tumor cell line (autologous tumor antigens), given here concurrently with standard immune checkpoint…
NCT03743298 - Trial result Spotlight
Melanoma
mRNA-4359 (PD-L1/IDO1 mRNA immunotherapy) + pembrolizumab drives 83% ORR in 1L metastatic melanoma (Phase 1/2)
mRNA-4359 is an intramuscular mRNA cancer antigen therapy encoding PD-L1 and IDO1 epitopes, designed to induce antigen-specific T cells against tumor and immunosuppressive cells, and was combined with pembrolizumab…
NCT05533697 - Trial result
Melanoma
Sotigalimab (intratumoral CD40 agonist) + pembrolizumab drives 50% ORR and abscopal responses in CPI‑naïve metastatic melanoma
Sotigalimab is an intratumoral, agonistic anti‑CD40 antibody designed to activate antigen-presenting cells (APCs) and “in situ” prime T cells; here it was combined with pembrolizumab (anti‑PD‑1) in a Phase I/II study…
NCT02706353 - New trial
Melanoma
Phase 2 fianlimab + cemiplimab tests dual LAG-3/PD-1 checkpoint blockade in resectable melanoma.
This Phase 2, open-label, randomized, parallel-assignment trial at UC Irvine evaluates perioperative “total neoadjuvant therapy” using fianlimab plus cemiplimab in patients with surgically resectable melanoma.…
NCT07527325 Exploratory - New trial
Melanoma
Phase I UD expanded NK vs TGF-β–imprinted NK (intratumoral) in cSCC/BCC
Ohio State University Comprehensive Cancer Center compares standard UD expanded NK cells with TGF-β–imprinted NK cells in cutaneous SCC/BCC using diagnostic biopsy → intratumoral injection → surgical excision. Most…
NCT07144384 Exploratory - Trial result
Melanoma
Encorafenib+Binimetinib (BRAF/MEK) Produces Rapid LMD Response and ~14-mo Survival (Case)
Encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) were re-introduced at reduced doses in a 69-year-old man with BRAF V600K metastatic melanoma who developed leptomeningeal disease (LMD) and had declined…
NCT05026983
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.